Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

GSK submits bepirovirsen for EMA review after trials hit primary endpoints

(Sharecast News) - Drugmaker GSK said on Friday that the European Medicines Agency will review its marketing authorisation application for the use of bepirovirsen, an investigational antisense oligonucleotide, in the treatment of adults with chronic hepatitis B. GSK said the regulatory submission to the EMA was based on positive results from its B-Well 1 and B-Well 2 Phase III trials - both of which met their primary endpoint, with bepirovirsen demonstrating a "statistically significant and clinically meaningful" functional cure rate.

The FTSE 100-listed firm noted that chronic hepatitis B remains a "public health concern" in Europe, with an estimated 3.2m people living with the condition. It also highlighted that the current standard of care, nucleos(t)ide analogues, often requires lifelong therapy and said the functional cure rate remains at typically only 1%.

GSK added that bepirovirsen was also being evaluated as a potential backbone therapy for future sequential treatment strategies aimed at expanding functional cure to broader patient populations. It has yet to be approved anywhere in the world.

As of 0815 GMT, GSK shares were down 0.34% at 2,040p.

Reporting by Iain Gilbert at Sharecast.com

See latest RNS on Investegate

Share this article

Related Sharecast Articles

Playtech FY profit to beat market expectations, hails strong Americas performance
(Sharecast News) - Playtech said on Tuesday that full-year profit was set to be ahead of analysts' expectations following better-than-expected trading from July to the end of October, driven by a continued strong performance in the Americas.
Travis Perkins to sell loss-making Toolstation Benelux for nominal €1
(Sharecast News) - Travis Perkins said on Tuesday that it has agreed to sell its loss-making Toolstation Benelux business for a nominal €1 to Fidelium Partners.
Vodafone lifts full-year guidance despite slide into red
(Sharecast News) - Telecoms giant Vodafone upped full-year guidance on Tuesday, despite a slide into the red and ongoing weakness in Germany.
4Imprint sees FY in line with expectations
(Sharecast News) - 4imprint said full-year results are set to be in line with expectations, with the board reaffirming guidance for 2026 revenue to be slightly above last year's $1.35bn and adjusted pre-tax profit of around $130m.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.